Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Wahrmann

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Transplantation Direct|March 21, 2020
High-activity Classical and Alternative Complement Pathway Genotypes-Association With Donor-specific Antibody-triggered Injury and Renal Allograft SurvivalBlanka Mező, Roman Reindl-Schwaighofer, Farsad Eskandary, et al.
Transplantation|April 3, 2020
CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft RejectionKonstantin Doberer, Johannes Kläger, Guido A Gualdoni, et al.
Journal of the American Society of Nephrology : JASN|December 16, 2017
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant RejectionFarsad Eskandary, Heinz Regele, Lukas Baumann, et al.
Cell Reports|March 14, 2023
The human placenta shapes the phenotype of decidual macrophagesSigrid Vondra, Anna-Lena Höbler, Andreas Ian Lackner, et al.
Frontiers in Medicine|May 9, 2022
Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated RejectionAnita Borski, Alexander Kainz, Nicolas Kozakowski, et al.
Cell Reports|January 14, 2023
The human placenta shapes the phenotype of decidual macrophagesSigrid Vondra, Anna-Lena Höbler, Andreas Ian Lackner, et al.
Trials|April 9, 2022
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trialKatharina A Mayer, Klemens Budde, Philip F Halloran, et al.
Frontiers in Cellular and Infection Microbiology|September 20, 2021
Identification of Immune Activation Markers in the Early Onset of COVID-19 InfectionJohannes J Kovarik, Anna K Kämpf, Fabian Gasser, et al.
The Journal of Allergy and Clinical Immunology|July 17, 2018
Allograft rejection is associated with development of functional IgE specific for donor MHC antigensAndreas M Farkas, Ulrike Baranyi, Georg A Böhmig, et al.
Medical Microbiology and Immunology|March 6, 2025
Stability of cytokine, cellular and clinical response to the intravenous LPS challenge repeated after one year: a healthy volunteer trialAnselm Jorda, Lena Pracher, Sabine Eberl, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Transplantation Direct|March 21, 2020
High-activity Classical and Alternative Complement Pathway Genotypes-Association With Donor-specific Antibody-triggered Injury and Renal Allograft SurvivalBlanka Mező, Roman Reindl-Schwaighofer, Farsad Eskandary, et al.
Transplantation|April 3, 2020
CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft RejectionKonstantin Doberer, Johannes Kläger, Guido A Gualdoni, et al.
Journal of the American Society of Nephrology : JASN|December 16, 2017
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant RejectionFarsad Eskandary, Heinz Regele, Lukas Baumann, et al.
Cell Reports|March 14, 2023
The human placenta shapes the phenotype of decidual macrophagesSigrid Vondra, Anna-Lena Höbler, Andreas Ian Lackner, et al.
Frontiers in Medicine|May 9, 2022
Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated RejectionAnita Borski, Alexander Kainz, Nicolas Kozakowski, et al.
Cell Reports|January 14, 2023
The human placenta shapes the phenotype of decidual macrophagesSigrid Vondra, Anna-Lena Höbler, Andreas Ian Lackner, et al.
Trials|April 9, 2022
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trialKatharina A Mayer, Klemens Budde, Philip F Halloran, et al.
Frontiers in Cellular and Infection Microbiology|September 20, 2021
Identification of Immune Activation Markers in the Early Onset of COVID-19 InfectionJohannes J Kovarik, Anna K Kämpf, Fabian Gasser, et al.
The Journal of Allergy and Clinical Immunology|July 17, 2018
Allograft rejection is associated with development of functional IgE specific for donor MHC antigensAndreas M Farkas, Ulrike Baranyi, Georg A Böhmig, et al.
Medical Microbiology and Immunology|March 6, 2025
Stability of cytokine, cellular and clinical response to the intravenous LPS challenge repeated after one year: a healthy volunteer trialAnselm Jorda, Lena Pracher, Sabine Eberl, et al.
Pageof 7